Breast Cancer Clinical Trials & Research at Providence Medical Group
In the U.S., breast cancer is the second most common cancer in women after
skin cancer. It can occur in both men and women. The most common type
of breast cancer is ductal carcinoma, which begins in the cells of the
ducts. Breast cancer can also begin in the cells of the lobules and in
other tissues in the breast. Invasive breast cancer is breast cancer that
has spread from where it began in the ducts or lobules to surrounding tissue.
Providence Medical Group is currently enrolling patients for the following
breast cancer clinical trials:
A Phase 2, Randomized, Open-Label Study Evaluating the Safety and Efficacy
of Magrolimab in Combination with Nab-Paclitaxel or Paclitaxel versus
Nab-Paclitaxel or Paclitaxel in Previously Untreated Patients with Metastatic
Triple-Negative Breast Cancer
Treatment agent: Magrolimab + Nap-Paclitaxel or Paclitaxel vs. Nab-Paxlitaxel
or Paclitaxel
PI: Jarrod Holmes, MD
Study Coordinator: Teresa Lund
Resources and Links:
https://clinicaltrials.gov/ct2/show/NCT04958785?term=NCT04958785&draw=2&rank=1
Sponsor: Gilead Sciences
Study to Assess the Effect of PF_06946860 on Appetite Following Subcutaneous
Administration to Patients with Anorexia and Advanced Cancer
Treatment agent: PF-06946860
PI: Sara Keck, MD
Study Coordinator: Melissa Phillips // Melissa.Phillips2@stjoe.org// (707)
521-3833 ext. 1313
Resources and Links:
https://clinicaltrials.gov/ct2/show/NCT04803305?term=PF-06946860&draw=2&rank=2
Sponsor: Pfizer
A Phase II, Multicenter, Open-label Study to Evaluate the Efficacy and
Safety of Trastuzumab Deruxtecan (T-DXd) for the Treatment of Unresectable
and/or Metastatic Solid Tumors Harboring HER2 Activating Mutations Regardless
of Tumor Histology
Treatment agent: Berzosertib, Topotecan Hydrochloride
PI:
Ian Anderson, MD
Study Coordinator: Camille Shaffer
Resources and Links:
https://clinicaltrials.gov/ct2/show/NCT04639219?term=04639219&draw=2&rank=1
Sponsor: AstraZeneca
Phase III Study to Assess AZD9833+ CDK4/6 Inhibitor in HR+/HER2-MBC With
Detectable ESR1m Before Progression (SERENA-6)
Treatment agent: AZD9833 + Palbociclib/Abemaciclib vs Letrozole/Anastrazole
+ Palbociclib/Abemaciclib
PI:
Manasa Vulchi, MD
Study Coordinator: Camille Shaffer // Camille.Shaffer@stjoe.org // (707)
521-3809 ext. 1182
Resources and Links: https://clinicaltrials.gov/ct2/show/NCT04964934?term=NCT04964934&draw=2&rank=1
Sponsor: AstraZeneca
Efficacy Evaluation of Enobosarm Monotherapy in Treatment of AR+/ER+/HER2-
Metastatic Breast Cancer (ARTEST)
Treatment agent: Enobosarm vs Esemestane, esemestane + everolimus, or SERM
PI:
Jarrod Holmes, MD
Study Coordinator: Teresa Lund // Teresa.Lund@stjoe.org // (707) 521-3803
ext. 1103
Resources and Links: https://clinicaltrials.gov/ct2/show/NCT04869943?term=NCT04869943&draw=2&rank=1
Sponsor: Veru Inc.
ASCENT-04 GS 548-6173:
Randomized Phase 3 Study of Sacituzumab Govitecan and Pembrolizumab Vs
Treatment of Physician’s Choice and Pembro in 1L Locally Advanced
Inoperable orMetastatic TNBC PDL1 +
Study Coordinator: Melissa Phillips // Melissa.Phillips2@stjoe.org// (707)
521-3833 ext. 1313
Key I/E: PDL1 pos
GS-US-586-6144:
Phase 2 Study of Magrolimab + sacituzumab govitecan in unresectable/metastatic
TNBC Previously Untreated Met TNBC
Study Coordinator: Teresa Lund // Teresa.Lund@stjoe.org // (707) 521-3803
ext. 1103
Key I/E: PDLI neg, 1 prior line Rx metastatic , prior taxane met or neoadj,
if PDL1+ then have recived
Rx: antiCD47 Ab blocks don’t eat me signal on tumors, can cause anemia
Abbvie 037:
Phase 1 Study to Determine the Safety, Tolerability, Pharmacokinetics,
and Preliminary Efficacy of Combinations of ABBV-927 (CD40 Ab)
Study Coordinator: Tracy x1136
Key I/E: Arms 1-3, PD after at least 1 prior Rx including taxane, no prior
platinum or immunoRx; Arm 4 1st line PD-L1
Rx: dose-escalation -> expansion, IV
PROFOUND:
Phase 1/2 Study of PRO1184 in Patients with Locally Advanced and/or Metastatic
Solid Tumors
Study Coordinator: Tracy x1136
Key I/E: no SOC options remaining, CrCl >=60, CNS mets if stable 4 wks
prior to study
Rx: PRO1184 is an ADC targeting Fra (folate receptor alpha)